The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Yilmaz, Musa [1 ]
Kantarjian, Hagop M. [2 ]
Ravandi, Farhad [2 ]
Jorgensen, Jeffrey L. [3 ]
Wang, Sa [3 ]
Garcia-Manero, Guillermo [2 ]
Cortes, Jorge E. [2 ]
Sasaki, Koji [2 ]
DiNardo, Courtney [2 ]
Kadia, Tapan [2 ]
Autry, Jane [2 ]
Garris, Rebecca [2 ]
Jabbour, Elias [2 ]
机构：
[1] Baylor Coll Med, Dept Hematol & Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease
    Kayser, Sabine
    Sartor, Chiara
    Luskin, Marlise R.
    Webster, Jonathan
    Giglio, Fabio
    Panitz, Nydia
    Brunner, Andrew M.
    Fante, Matthias
    Lutz, Christoph
    Wolff, Daniel
    Ho, Anthony D.
    Levis, Mark
    Schlenk, Richard F.
    Papayannidis, Cristina
    BLOOD, 2021, 138
  • [22] Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).
    Frey, Noelle V.
    Shaw, Pamela A.
    Hexner, Elizabeth O.
    Gill, Saar
    Marcucci, Katherine
    Luger, Selina M.
    Mangan, James K.
    Grupp, Stephan A.
    Maude, Shannon L.
    Ericson, Solveig
    Levine, Bruce
    Lacey, Simon F.
    Melenhorst, Jan J.
    June, Carl H.
    Porter, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
    Jabbour, Elias
    Gokbuget, Nicola
    Advani, Anjali S.
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Martinelli, Giovanni
    O'Brien, Susan Mary
    Wang, Tao
    Laird, Douglas
    Vandendries, Erik
    Neuhof, Alexander
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Assi, Rita
    Kantarjian, Hagop M.
    Khouri, Rita
    Ravandi, Farhad
    Kebriaei, Partow
    Short, Nicholas J.
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Champlin, Richard E.
    Kadia, Tapan
    Cortes, Jorge E.
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Takahashi, Koichi
    Sasaki, Koji
    Jacob, Jovitta
    Manzoor, Ameena
    Garris, Rebecca
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2017, 130
  • [25] Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S192 - S193
  • [26] Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
    Zhu, Min
    Kratzer, Andrea
    Johnson, Jessica
    Holland, Chris
    Brandl, Christian
    Singh, Indrajeet
    Wolf, Andreas
    Doshi, Sameer
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Minimal residual disease (MRD) and risk-oriented therapy in adult acute lymphoblastic leukemia (ALL)
    Bassan, R
    Spinelli, O
    Oldani, E
    Intermesoli, T
    Tosi, M
    Giuseppe, R
    Pogliani, EM
    Angelucci, E
    Fabris, P
    Lambertenghi-Deliliers, G
    Polistena, P
    Di Bona, E
    Ciceri, F
    Leoni, F
    Minotto, C
    Mattei, D
    Musso, M
    Barbui, T
    Rambaldi, A
    BLOOD, 2005, 106 (11) : 522A - 522A
  • [28] Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
    Kantarjian, Hagop M.
    Logan, Aaron C.
    Zaman, Faraz
    Goekbuget, Nicola
    Bargou, Ralf C.
    Zeng, Yi
    Zugmaier, Gerhard
    Locatelli, Franco
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
  • [29] Cost-Effectiveness of KTE-X19 for Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the United States
    Shah, Bijal
    Smith, Nathaniel
    Raad, Angie
    Feng, Chaoling
    Castaigne, Gab
    Masouleh, Behzad Kharabi
    Malone, Daniel
    Bishop, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S272 - S273
  • [30] Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
    Li, Shiqi
    Wang, Xinxin
    Yuan, Zhongtao
    Liu, Lin
    Li, Yu
    Liu, Jia
    He, Jiaping
    Li, Zhimin
    Zhao, Wei
    Ge, Jianning
    Ni, Yajin
    Shen, Lianjun
    Cao, Wei
    Zhang, Xi
    Sersch, Martina
    Wang, Sanbin
    CANCER RESEARCH, 2022, 82 (12)
12345